-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:AMD第一季營收成長38%至103億美元,高於預期的33%,每股盈餘為1.37美元(+43%),也高於市場普遍預期的1.29美元。資料中心業務營收達58億美元(+57%),超出預期,目前佔總銷售額的56%,凸顯了人工智慧基礎設施轉型。 MI450系列和Helios機架式解決方案的客戶參與度不斷提高,這令我們倍感鼓舞。預測結果超出預期,與Meta的合作也驗證了AMD的人工智慧路線圖,並計畫部署高達6GW的Instinct GPU。第二季營收指引為112億美元(+46%),高於市場預期的105億美元,反映了AMD對產品路線圖的信心。 55%的毛利率(上調1個百分點)和創紀錄的26億美元自由現金流(毛利率25%)表明,AMD有能力在實現盈利增長的同時,為戰略投資提供資金。我們相信,隨著AMD擴大供應規模以滿足市場需求,伺服器業務的成長速度將顯著加快,大規模部署專案也將使成長軌跡更加清晰可見。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.